Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Indolent Lymphomas”

306 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 306 results

Large-scale testing (Phase 3)UnknownNCT00091676
What this trial is testing

Study of the BiovaxId Tumor Derived Idiotype Vaccine in Patients With Follicular Lymphoma

Who this might be right for
Non-Hodgkins Lymphoma
Biovest International 629
Large-scale testing (Phase 3)Looking for participantsNCT06091254
What this trial is testing

A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma

Who this might be right for
Follicular Lymphoma (FL)
Regeneron Pharmaceuticals 822
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07441954
What this trial is testing

Pomalidomide Combined With Obinutuzumab in the Treatment of Patients With Relapsed/Refractory Indolent Lymphoma

Who this might be right for
Indolent Lymphoma
Institute of Hematology & Blood Diseases Hospital, China 53
Testing effectiveness (Phase 2)Ended earlyNCT00493454
What this trial is testing

Ibritumomab Tiuxetan for Treatment of Non-Follicular CD20+ Indolent Lymphomas

Who this might be right for
Lymphoma
M.D. Anderson Cancer Center 6
Not applicableStudy completedNCT02072967
What this trial is testing

Ribomustin in the Second Line Therapy of Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma

Who this might be right for
Lymphoma, Non-Hodgkin
Astellas Pharma Europe B.V. 97
Early research (Phase 1)Active Not RecruitingNCT05753501
What this trial is testing

Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies

Who this might be right for
Hematologic Cancer
AbbVie 135
Testing effectiveness (Phase 2)Study completedNCT02086175
What this trial is testing

Clinical Trial of Rituxan and B-Glucan PGG in Relapsed Indolent Non-Hodgkin Lymphoma

Who this might be right for
Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphomas
Dana-Farber Cancer Institute 25
Testing effectiveness (Phase 2)Temporarily pausedNCT07098364
What this trial is testing

ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed/Refractory Large B-Cell Lymphoma

Who this might be right for
Recurrent Diffuse Large B-Cell LymphomaRecurrent Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedRecurrent Grade 3b Follicular Lymphoma+9 more
Fred Hutchinson Cancer Center 33
Early research (Phase 1)Study completedNCT01317901
What this trial is testing

TRU-016 in Combination With Rituximab and Bendamustine in Subjects With Relapsed Indolent Lymphoma

Who this might be right for
B-cell Small Lymphocytic Lymphoma Recurrent
Aptevo Therapeutics 12
Early research (Phase 1)Study completedNCT04599634
What this trial is testing

Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies

Who this might be right for
Follicular LymphomaMarginal Zone LymphomaMantle Cell Lymphoma+2 more
National Cancer Institute (NCI) 11
Testing effectiveness (Phase 2)Study completedNCT00576758
What this trial is testing

GAUSS: A Study of Obinutuzumab (RO5072759) in Patients With Indolent Non-Hodgkin's Lymphoma

Who this might be right for
Non-Hodgkin's Lymphoma
Hoffmann-La Roche 175
Testing effectiveness (Phase 2)Study completedNCT00076349
What this trial is testing

SDX-105 in Combination With Rituxan for Patients With Relapsed Indolent or Mantle Cell Non-Hodgkin's Lymphoma (NHL)

Who this might be right for
Non-Hodgkin's Lymphoma
Cephalon 66
Testing effectiveness (Phase 2)Study completedNCT00764517
What this trial is testing

Vorinostat, Cladribine, and Rituximab in Treating Patients With Mantle Cell Lymphoma, Relapsed Chronic Lymphocytic Leukemia, or Relapsed B Cell Non-Hodgkin's Lymphoma

Who this might be right for
Recurrent B-Cell Non-Hodgkin LymphomaRecurrent Chronic Lymphocytic LeukemiaRecurrent Indolent Adult Non-Hodgkin Lymphoma+1 more
OHSU Knight Cancer Institute 57
Testing effectiveness (Phase 2)Study completedNCT00509379
What this trial is testing

Non-randomized Safety Study With Bortezomib/Rituximab in Relapsed/Refractory Indolent Lymphoma

Who this might be right for
LymphomaNon-Hodgkin Lymphoma
Gruppo Italiano Multiregionale per lo studio dei Linfomi e delle Leucemie 48
Early research (Phase 1)Study completedNCT00271050
What this trial is testing

External Beam Radiotherapy and Zevalin for Management of Indolent B-Cell Non-Hodgkin's Lymphoma

Who this might be right for
Lymphoma, B-Cell
The Cleveland Clinic 12
Testing effectiveness (Phase 2)Study completedNCT03520920
What this trial is testing

BTK Inhibitor BGB-3111 in Chinese Participants With Diffuse Large B-Cell Lymphoma (Non-GCB) and Indolent Lymphoma (FL and MZL)

Who this might be right for
Marginal Zone LymphomaFollicular LymphomaDiffuse Large B-Cell Lymphoma
BeiGene 41
Not applicableLooking for participantsNCT06860880
What this trial is testing

Combating Cancer-Related Fatigue: A Personalized Supportive Care Program

Who this might be right for
Indolent LymphomasLymphomaChronic Lymphocytic Leukemia+6 more
UNC Lineberger Comprehensive Cancer Center 40
Early research (Phase 1)Ended earlyNCT04431635
What this trial is testing

Dose De-escalation Study of the PI3k Alpha/Delta Inhibitor, Copanlisib Given in Combination With the Immunotherapeutic Agents, Nivolumab and Rituximab in Patients With Relapsed/Refractory Indolent Lymphoma

Who this might be right for
Indolent Lymphoma
University of Michigan Rogel Cancer Center 6
Testing effectiveness (Phase 2)Study completedNCT00720876
What this trial is testing

Vorinostat and Rituximab in Treating Patients With Indolent Non-Hodgkin Lymphoma

Who this might be right for
Lymphoma
City of Hope Medical Center 30
Early research (Phase 1)Active Not RecruitingNCT03884998
What this trial is testing

Copanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgkin Lymphoma

Who this might be right for
Chronic Lymphocytic LeukemiaDiffuse Large B-Cell LymphomaFollicular Lymphoma+4 more
City of Hope Medical Center 27
Next Page